Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .
Sponsor: JHM BioPharma (Tonghua) Co. , Ltd.
Summary
This is a phase III clinical study to evaluate the efficacy and safety of recombinant botulinum toxin type A(Eveotox)in adult patients with upper limb spasticity. The purpose of this study was to observe efficacy and safety of Eveotox compared with placebo in adult patients with upper limb spasticity.
Official title: A Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) in Adult Patients With Upper Limb Spasticity
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
207
Start Date
2025-12-11
Completion Date
2028-01
Last Updated
2026-08-05
Healthy Volunteers
No
Conditions
Interventions
Recombinant Botulinum Toxin Type A for injection
Recombinant Botulinum Toxin Type A for injection
Placebo
Placebo will be administered in double-blind fashion during treatment cycle 1 only
Locations (12)
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China
The Second Hospital of Hebei Medical Hospital
Shijiazhuang, Hebei, China
Luoyang Central Hospital
Luoyang, Henan, China
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Huai 'an Second People's Hospital
Huai'an, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
Shengjing Hospital affiliated to China Medical University
Shenyang, Liaoning, China
Yantai Mountain Hospital
Yantai, Shandong, China
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Yangzhi Affiliated Rehabilitation Hospital of Tongji University
Shanghai, Shanghai Municipality, China